Johnson & Johnson announced it has discontinued a mid stage clinical trial of an experimental drug for moderate to severe atopic dermatitis after the treatment failed to meet efficacy targets. While the drug was shown to be safe and well tolerated, results from an interim analysis did not justify continued development.
Details of the Discontinued Trial
The drug, known as JNJ 5939, was being studied in patients with atopic dermatitis, commonly referred to as eczema. This chronic condition causes skin inflammation, redness, and intense itching, often requiring long term treatment.
Johnson & Johnson said the therapy did not achieve the level of effectiveness required to move forward, describing the benchmark as a high bar given the competitive treatment landscape.
Company Commitment to Dermatology
Despite the setback, Johnson & Johnson reaffirmed its commitment to developing new therapies for atopic dermatitis, which affects more than 100 million people worldwide. The company emphasized that discontinuing one candidate allows greater focus on other programs with stronger potential.
Ongoing development efforts include several bispecific antibody candidates, NM26, PX128, and PX130, as well as an oral STAT6 inhibitor known as KP 723.
Highly Competitive Treatment Market
The atopic dermatitis market already includes multiple approved therapies, making it difficult for new drugs to stand out. Leading treatments include Dupixent from Sanofi and Regeneron, Rinvoq from AbbVie, Cibinqo from Pfizer, and Ebglyss from Eli Lilly.
Patients also rely on established generic medications such as cetirizine, further raising the bar for experimental therapies to demonstrate meaningful clinical improvement.
Conclusion
The decision to halt development of JNJ 5939 highlights the challenges of advancing new drugs in a crowded and well established therapeutic area. While the trial outcome represents a near term setback, Johnson & Johnson continues to pursue alternative approaches aimed at improving treatment options for people living with atopic dermatitis.
